Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.

Bhatia S, Afanasiev O, Nghiem P.

Curr Oncol Rep. 2011 Dec;13(6):488-97. doi: 10.1007/s11912-011-0197-5. Review.

2.

Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.

Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM, Nghiem P.

Clin Cancer Res. 2011 Nov 1;17(21):6671-80. doi: 10.1158/1078-0432.CCR-11-1513. Epub 2011 Sep 9.

3.

Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.

Vandeven N, Nghiem P.

Immunotherapy. 2016 Jul;8(8):907-21. doi: 10.2217/imt-2016-0009. Review.

PMID:
27381685
4.

Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.

Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem P.

Cancer Immunol Res. 2014 Jan;2(1):27-36. doi: 10.1158/2326-6066.CIR-13-0087.

5.

The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma.

Amber K, McLeod MP, Nouri K.

Dermatol Surg. 2013 Feb;39(2):232-8. doi: 10.1111/dsu.12079. Review.

PMID:
23387356
6.

Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.

Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, Ibrani D, Koelle DM, Nghiem P.

Clin Cancer Res. 2013 Oct 1;19(19):5351-60. doi: 10.1158/1078-0432.CCR-13-0035. Epub 2013 Aug 6.

7.

Merkel cell carcinoma: recent insights and new treatment options.

Schrama D, Ugurel S, Becker JC.

Curr Opin Oncol. 2012 Mar;24(2):141-9. doi: 10.1097/CCO.0b013e32834fc9fe. Review.

PMID:
22234254
8.

Update on the biology and clinical management of Merkel cell carcinoma.

Thakuria M, LeBoeuf NR, Rabinowits G.

Am Soc Clin Oncol Educ Book. 2014:e405-10. doi: 10.14694/EdBook_AM.2014.34.e405. Review.

9.

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.

Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, Chan TA, Nghiem P, Lifton RP, Choi J.

Oncotarget. 2016 Jan 19;7(3):3403-15. doi: 10.18632/oncotarget.6494.

10.

Merkel cell carcinoma: Do you know your guidelines?

Miles BA, Goldenberg D; Education Committee of the American Head and Neck Society (AHNS).

Head Neck. 2016 May;38(5):647-52. doi: 10.1002/hed.24359. Epub 2015 Dec 30. Review.

PMID:
26716756
11.

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube JM.

Cancer Immunol Res. 2013 Jul;1(1):54-63. doi: 10.1158/2326-6066.CIR-13-0034.

12.

Correlation of Merkel cell polyomavirus positivity with PDGFRα mutations and survivin expression in Merkel cell carcinoma.

Batinica M, Akgül B, Silling S, Mauch C, Zigrino P.

J Dermatol Sci. 2015 Jul;79(1):43-9. doi: 10.1016/j.jdermsci.2015.04.002. Epub 2015 Apr 14.

PMID:
25936870
13.

Merkel cell polyomavirus in merkel cell carcinoma: clinical and therapeutic perspectives.

Samimi M, Gardair C, Nicol JT, Arnold F, Touzé A, Coursaget P.

Semin Oncol. 2015 Apr;42(2):347-58. doi: 10.1053/j.seminoncol.2014.12.021. Epub 2014 Dec 31. Review.

PMID:
25843739
14.

Merkel cell carcinoma - recent advances in the biology, diagnostics and treatment.

Czapiewski P, Biernat W.

Int J Biochem Cell Biol. 2014 Aug;53:536-46. doi: 10.1016/j.biocel.2014.04.023. Epub 2014 May 5. Review.

PMID:
24811434
15.

Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P.

Curr Treat Options Oncol. 2013 Jun;14(2):249-63. doi: 10.1007/s11864-013-0225-9.

16.

Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice.

Guastafierro A, Feng H, Thant M, Kirkwood JM, Chang Y, Moore PS, Shuda M.

J Virol Methods. 2013 Jan;187(1):6-14. doi: 10.1016/j.jviromet.2012.10.001. Epub 2012 Oct 18.

17.

Improved detection suggests all Merkel cell carcinomas harbor Merkel polyomavirus.

Rodig SJ, Cheng J, Wardzala J, DoRosario A, Scanlon JJ, Laga AC, Martinez-Fernandez A, Barletta JA, Bellizzi AM, Sadasivam S, Holloway DT, Cooper DJ, Kupper TS, Wang LC, DeCaprio JA.

J Clin Invest. 2012 Dec;122(12):4645-53. doi: 10.1172/JCI64116. Epub 2012 Nov 1.

18.

Human Merkel cell polyomavirus: virological background and clinical implications.

Coursaget P, Samimi M, Nicol JT, Gardair C, Touzé A.

APMIS. 2013 Aug;121(8):755-69. doi: 10.1111/apm.12122. Epub 2013 Jun 19. Review.

PMID:
23781869
19.

Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma.

Faust H, Andersson K, Ekström J, Hortlund M, Robsahm TE, Dillner J.

Int J Cancer. 2014 Feb 15;134(4):844-8. doi: 10.1002/ijc.28419. Epub 2013 Aug 29.

20.

Trichodysplasia spinulosa-associated polyomavirus (TSV) and Merkel cell polyomavirus: correlation between humoral and cellular immunity stronger with TSV.

Kumar A, Kantele A, Järvinen T, Chen T, Kavola H, Sadeghi M, Hedman K, Franssila R.

PLoS One. 2012;7(9):e45773. doi: 10.1371/journal.pone.0045773. Epub 2012 Sep 24.

Supplemental Content

Support Center